Compile Data Set for Download or QSAR
Report error Found 130 Enz. Inhib. hit(s) with all data for entry = 12483
TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699117(US20240327430, Example 1 | US12145945, Example 1)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699118(US20240327430, Example 2 | US12145945, Example 2)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699164(US20240327430, Example 3 | US12145945, Example 3)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699165(US20240327430, Example 4 | US12145945, Example 4)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699166(US20240327430, Example 5 | US12145945, Example 5)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699167(US20240327430, Example 6 | US12145945, Example 6)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699168(US20240327430, Example 7 | US12145945, Example 7)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699177(US20240327430, Example 17 | US12145945, Example 17)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699185(US20240327430, Example 26 | US12145945, Example 19)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699179(US20240327430, Example 20 | US12145945, Example 20)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699180(US20240327430, Example 21 | US12145945, Example 21)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699181(US20240327430, Example 22 | US12145945, Example 22)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699182(US20240327430, Example 23 | US12145945, Example 23)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699183(US20240327430, Example 24 | US12145945, Example 24)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699184(US20240327430, Example 25 | US12145945, Example 25)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM705365(US12145945, Example 26)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699187(US20240327430, Example 28 | US12145945, Example 28)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699188(US20240327430, Example 29 | US12145945, Example 29)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699189(US20240327430, Example 30 | US12145945, Example 30)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699190(US20240327430, Example 31 | US12145945, Example 31)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699191(US20240327430, Example 32 | US12145945, Example 32)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699228(US20240327430, Example 68 | US12145945, Example 12...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699193(US20240327430, Example 34 | US12145945, Example 34)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699194(US20240327430, Example 35 | US12145945, Example 35)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699196(US20240327430, Example 36B | US12145945, Example 3...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699197(US20240327430, Example 37 | US12145945, Example 37)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699198(US20240327430, Example 38 | US12145945, Example 38)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699201(US20240327430, Example 41 | US12145945, Example 41)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699202(US20240327430, Example 42 | US12145945, Example 42)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699203(US20240327430, Example 43 | US12145945, Example 43)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699204(US20240327430, Example 44 | US12145945, Example 44)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699205(US20240327430, Example 45 | US12145945, Example 45)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699206(US20240327430, Example 46 | US12145945, Example 46)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699207(US20240327430, Example 47 | US12145945, Example 47)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699208(US20240327430, Example 48 | US12145945, Example 48)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699209(US20240327430, Example 49 | US12145945, Example 49)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699210(US20240327430, Example 50 | US12145945, Example 50)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699211(US20240327430, Example 51 | US12145945, Example 51)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699212(US20240327430, Example 52 | US12145945, Example 52)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699213(US20240327430, Example 53 | US12145945, Example 53)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699214(Synthesis of 2′-chloro-N-(5-{3,8-diazabicycl...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699215(US20240327430, Example 55 | US12145945, Example 55)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699216(US20240327430, Example 56 | US12145945, Example 56)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699217(US20240327430, Example 57 | US12145945, Example 57)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699218(Synthesis of 2′-chloro-5′-methoxy-6-me...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699219(US20240327430, Example 59 | US12145945, Example 59)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699220(US20240327430, Example 60 | US12145945, Example 60)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699221(US20240327430, Example 61 | US12145945, Example 61)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699222(US20240327430, Example 62 | US12145945, Example 62)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699223(US20240327430, Example 63 | US12145945, Example 63)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
Go to US Patent

Displayed 1 to 50 (of 130 total ) | Next | Last >>
Jump to: